Zts stock price with expanding global pet ownership

With expanding global pet ownership trends, ZTS stock price could benefit from tailwinds in premium veterinary product demand over the next decade. Zoetis (NYSE: ZTS) is the top dog in pet and livestock healthcare, providing medicines, vaccines, diagnostics, and more for owners of eight animal species across the globe. Powered by its 17 blockbuster drugs that earn over $100 million annually, Zoetis is a well-diversified innovation machine . ZTS should be on investors' short list because of its impressive earnings fundamentals, a good Zacks Rank, and strong Momentum and VGM Style Scores. Technical traders view ZTS stock price breaking resistance at $172 as confirmation of a new upward channel. RSI levels remain neutral, indicating room for further rally before overbought territory.